Feasibility Assessments for Comparative Evidence Generation: Building on the Cope et al. (2014) Framework in the Era of EU JCA
How should feasibility assessments for indirect treatment comparisons evolve in the era of EU JCA? Our expanded framework builds on Cope et al. (2014) and adds five new domains.
The new discount on combination drug therapies in Germany: First numbers and assessment from a payor perspective
The “GKV Financial Stabilization Act” (GKV-FinStG), introduced in November 2022, brought several changes to the German pricing system for drugs, including a novel discount on pre-selected combination therapies. From October 2023 onwards, German statutory health insurance funds (SHIs) are entitled to a discount of 20 percent of the manufacturers’ prices on outpatient drugs that are prescribed in combination with another drug (for new drugs regulated by AMNOG) as designated by the “Gemeinsamer Bundesausschuss” (G-BA; §35a (3) sentence 4 SGB V). The German government expected medium-term savings of approximately €185 million per year.
ITC Feasibility Reporting Checklist
This checklist is designed to support high-quality, regulation-aligned ITC submissions for EU Joint Clinical Assessment.
It helps teams identify and address key reporting requirements early reducing the risk of delays or rejected assessments.
EU JCA SYSTEMATIC LITERATURE REVIEW (SLR) PROTOCOL CHECKLIST
Stay aligned with EU JCA requirements for systematic literature reviews. This checklist covers areas like defining PICOs, selecting relevant comparators, documenting search strategies, and planning meta-analyses.
Considerations for Selection of Fit for-Purpose Data in the US and Japan
The choice of data when starting an RWE study is critical. Each option—whether administrative claims, electronic medical records, registries, or surveys—offers unique strengths and limitations. Selecting the right one depends on your research objectives and the nuances of the healthcare system where the data originates.
The European Health Technology Assessment for emerging medicinal products
The European Health Technology Assessment (EU-HTA) aims to harmonise HTA across Europe, enhancing efficiency and reducing duplication of work for national authorities. This paper explores key components of the EU-HTA framework, challenges, future perspectives, and implications for pharmaceutical companies, primarily concentrating on drug evaluation over medical devices
Strategic Evidence Generation Planning: Objectives, Requirements, and Processes
Scientific evidence needs might differ substantially between the different stakeholders, but they also vary between countries due to different philosophies in the assessment of healthcare interventions. This requires early Global Evidence Generation planning. This paper deals with the process of developing an Evidence Generation Plan (EGP).